ZA200708029B - Metabolites for NK-1 antagonists for emesis - Google Patents
Metabolites for NK-1 antagonists for emesisInfo
- Publication number
- ZA200708029B ZA200708029B ZA200708029A ZA200708029A ZA200708029B ZA 200708029 B ZA200708029 B ZA 200708029B ZA 200708029 A ZA200708029 A ZA 200708029A ZA 200708029 A ZA200708029 A ZA 200708029A ZA 200708029 B ZA200708029 B ZA 200708029B
- Authority
- ZA
- South Africa
- Prior art keywords
- emesis
- metabolites
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05102359 | 2005-03-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200708029B true ZA200708029B (en) | 2008-11-26 |
Family
ID=36587133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200708029A ZA200708029B (en) | 2005-03-23 | 2007-09-18 | Metabolites for NK-1 antagonists for emesis |
Country Status (22)
Country | Link |
---|---|
US (1) | US7211579B2 (es) |
EP (1) | EP1863767B1 (es) |
JP (1) | JP4768010B2 (es) |
KR (1) | KR100903224B1 (es) |
CN (1) | CN101146775B (es) |
AR (1) | AR052949A1 (es) |
AT (1) | ATE425144T1 (es) |
AU (1) | AU2006226665B2 (es) |
BR (1) | BRPI0609699A2 (es) |
CA (1) | CA2602445C (es) |
DE (1) | DE602006005624D1 (es) |
DK (1) | DK1863767T3 (es) |
ES (1) | ES2320590T3 (es) |
IL (1) | IL185689A (es) |
MX (1) | MX2007011489A (es) |
NO (1) | NO20074622L (es) |
PL (1) | PL1863767T3 (es) |
PT (1) | PT1863767E (es) |
RU (1) | RU2404969C2 (es) |
TW (1) | TWI316056B (es) |
WO (1) | WO2006099968A1 (es) |
ZA (1) | ZA200708029B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007000198A (es) | 2004-07-06 | 2007-03-15 | Hoffmann La Roche | Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1. |
US8426450B1 (en) * | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
US9403772B2 (en) | 2011-11-29 | 2016-08-02 | Helsinn Healthcare Sa | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |
CN105745198B (zh) | 2013-11-08 | 2018-09-21 | 橘生药品工业株式会社 | 羧甲基哌啶衍生物 |
EP3140007A1 (en) * | 2014-05-05 | 2017-03-15 | Apicore US LLC | Methods of making netupitant and intermediates thereof |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
CN112174881B (zh) * | 2019-07-04 | 2022-06-21 | 上海森辉医药有限公司 | 一种奈妥匹坦的衍生物及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4745123A (en) | 1986-02-18 | 1988-05-17 | Warner-Lambert Company | Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
SG52217A1 (en) | 1993-12-29 | 1998-09-28 | Merck Sharp & Dohme | Substituted morpholine derivatives and their use as therapeutic agents |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
PT1394150E (pt) | 1999-02-24 | 2011-02-17 | Hoffmann La Roche | Derivados de 4-fenilpiridina e a sua utilização como antagonistas dos receptores de nc-1 |
EP1103545B1 (en) * | 1999-11-29 | 2003-11-05 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
WO2001085173A1 (en) * | 2000-05-10 | 2001-11-15 | Bristol-Myers Squibb Company | Alkylamine derivatives of dihydropyridine npy antagonists |
SI1303490T1 (sl) * | 2000-07-14 | 2008-10-31 | Hoffmann La Roche | N-oksidi kot predzdravila NK 1 receptorskega antagonista 4-fenil-piridin derivatov |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
EP1643998B1 (en) * | 2003-07-03 | 2007-08-29 | F. Hoffmann-La Roche Ag | Dual nk1/nk3 antagonists for treating schizophrenia |
-
2006
- 2006-03-14 AT AT06707550T patent/ATE425144T1/de active
- 2006-03-14 DK DK06707550T patent/DK1863767T3/da active
- 2006-03-14 PL PL06707550T patent/PL1863767T3/pl unknown
- 2006-03-14 JP JP2008502283A patent/JP4768010B2/ja not_active Expired - Fee Related
- 2006-03-14 WO PCT/EP2006/002313 patent/WO2006099968A1/en active Application Filing
- 2006-03-14 PT PT06707550T patent/PT1863767E/pt unknown
- 2006-03-14 RU RU2007134901/04A patent/RU2404969C2/ru not_active IP Right Cessation
- 2006-03-14 DE DE602006005624T patent/DE602006005624D1/de active Active
- 2006-03-14 MX MX2007011489A patent/MX2007011489A/es active IP Right Grant
- 2006-03-14 KR KR1020077021748A patent/KR100903224B1/ko active IP Right Grant
- 2006-03-14 CA CA2602445A patent/CA2602445C/en not_active Expired - Fee Related
- 2006-03-14 ES ES06707550T patent/ES2320590T3/es active Active
- 2006-03-14 AU AU2006226665A patent/AU2006226665B2/en not_active Ceased
- 2006-03-14 BR BRPI0609699-9A patent/BRPI0609699A2/pt not_active IP Right Cessation
- 2006-03-14 CN CN2006800094426A patent/CN101146775B/zh active Active
- 2006-03-14 EP EP06707550A patent/EP1863767B1/en active Active
- 2006-03-15 US US11/376,042 patent/US7211579B2/en active Active
- 2006-03-20 TW TW095109514A patent/TWI316056B/zh not_active IP Right Cessation
- 2006-03-21 AR ARP060101093A patent/AR052949A1/es unknown
-
2007
- 2007-09-03 IL IL185689A patent/IL185689A/en not_active IP Right Cessation
- 2007-09-12 NO NO20074622A patent/NO20074622L/no not_active Application Discontinuation
- 2007-09-18 ZA ZA200708029A patent/ZA200708029B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DK1863767T3 (da) | 2009-05-04 |
IL185689A (en) | 2012-05-31 |
CA2602445A1 (en) | 2006-09-28 |
PL1863767T3 (pl) | 2009-08-31 |
ATE425144T1 (de) | 2009-03-15 |
JP4768010B2 (ja) | 2011-09-07 |
US20060217393A1 (en) | 2006-09-28 |
BRPI0609699A2 (pt) | 2010-04-20 |
DE602006005624D1 (de) | 2009-04-23 |
CN101146775A (zh) | 2008-03-19 |
CN101146775B (zh) | 2012-07-18 |
MX2007011489A (es) | 2007-10-11 |
KR20070107146A (ko) | 2007-11-06 |
EP1863767A1 (en) | 2007-12-12 |
JP2008534454A (ja) | 2008-08-28 |
AU2006226665A1 (en) | 2006-09-28 |
IL185689A0 (en) | 2008-01-06 |
WO2006099968A1 (en) | 2006-09-28 |
TW200700390A (en) | 2007-01-01 |
RU2007134901A (ru) | 2009-04-27 |
TWI316056B (en) | 2009-10-21 |
EP1863767B1 (en) | 2009-03-11 |
KR100903224B1 (ko) | 2009-06-17 |
AU2006226665B2 (en) | 2011-01-27 |
RU2404969C2 (ru) | 2010-11-27 |
AR052949A1 (es) | 2007-04-11 |
US7211579B2 (en) | 2007-05-01 |
ES2320590T3 (es) | 2009-05-25 |
NO20074622L (no) | 2007-10-18 |
PT1863767E (pt) | 2009-03-27 |
CA2602445C (en) | 2013-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI370820B (en) | Fused heterocyclic compounds | |
ZA200803811B (en) | Neuropolin antagonists | |
TWI318206B (en) | Histamine-3 receptor antagonists | |
IL190280A0 (en) | Fused heterocyclic compounds useful as kinase modulators | |
EP2015752A4 (en) | P13 Kinase Antagonists | |
GB0509275D0 (en) | Synthetic receptor | |
PL1963369T3 (pl) | Antagoniści IL-21 | |
GB2428609B (en) | Chuck | |
HK1123038A1 (en) | Heterocyclic compounds | |
PL1863803T3 (pl) | Podstawione piperydyny | |
IL190686A0 (en) | Il-21 receptor antagonists | |
GB0504302D0 (en) | Markers for melanoma | |
ZA200708029B (en) | Metabolites for NK-1 antagonists for emesis | |
GB0509276D0 (en) | Synthetic receptor | |
ZA200802549B (en) | Fused heterocyclic compounds useful as kinase modulators | |
IL192045A0 (en) | Antitumour compounds | |
ZA200803017B (en) | Heterocyclic compounds | |
HU0500524D0 (en) | Equipment for energy-economical alcohol-distillatory | |
ZA200708844B (en) | Fused heterocyclic compounds | |
ZA200805009B (en) | Fused heterocyclic compound | |
EP1904776A4 (en) | ARRANGEMENT OF TOOL EQUIPMENT | |
ZA200711107B (en) | Arrangement for controlling pressure-fluid-operated drilling equipment | |
GB0516946D0 (en) | Receptor | |
GB0516617D0 (en) | EP2 Receptor antagonists | |
HK1117534A1 (en) | Fused heterocyclic compounds useful as kinase modulators |